Research programme: p38 MAP kinase inhibitors - Bristol-Myers Squibb
Alternative Names: BMS-480188; BMS-487418; BMS-626531; BMS-640994Latest Information Update: 04 Nov 2017
At a glance
- Originator Bristol-Myers Squibb
- Class Amides; Thiazoles
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA
- 08 Sep 2010 Preclinical development is ongoing in USA
- 20 Aug 2009 Pharmacodynamics and pharmacokinetics data from preclinical trials in Inflammation presented at the 238th American Chemical Society National Meeting (238th-ACS-2009)